Close Menu
Mental Health

Novo Nordisk diabetes drug shows signs of improving patients’ mental health in a study

Novo Nordisk diabetes drug shows signs of improving patients’ mental health in a studyAdvertisementEditor

Ulrich Quistgaard

Tel.: +45 3330 8349

We take responsibility for the content and are signed up to Pressenævnet

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

About MedWatch

MedWatch is a part of Watch Medier.

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Publisher

JP/Politiken Media Group Ltd

Copyright © MedWatch — All rights reserved

Swedish university Karolinska Institutet is calling for controlled clinical trials to be conducted to confirm the results.Diabetes and obesity are associated with an increased risk of mental health disorders and vice versa. | Photo: Hollie AdamsDiabetes and obesity are associated with an increased risk of mental health disorders and vice versa. | Photo: Hollie Adams

MARKETWIRE ‎

20 March 2026at 08:02

A large-scale database study from the Karolinska Institute, a Swedish medical university, suggests that Novo Nordisk’s drug semaglutide, which is included in the type 2 diabetes medication Ozempic (semaglutide), improves patients’ mental health, the institute writes in a press release.

Related articlesNovo Nordisk is working with the FDA to resolve production challenges in New Jersey. Pictured here is a production employee from the New Hampshire facility.MedWatch has contacted Novo Nordisk for a comment on the new trial, but the Danish pharmaceutical company does not wish to comment on the trial. | Photo: Finn Frandsen

When Christophe Bourdon took over as CEO of Leo Pharma, tragedy struck: “You realize how brutal life can be”

Subscription

Trade deal with US is one step closer to EU approval

Adam Steensberg is CEO of the Danish biotech company Zealand Pharma. | Foto: Stine Bidstrup

Did you read?Subscription

Lars Rebien Sørensen is chairman of both Novo Nordisk and the Novo Nordisk Foundation. | Foto: Novo Nordisk Fonden / PR

Did you read?Subscription

Anders Hedegaard served as managing director of GN Hearing from 2014 to 2018. He believes that GN has sold off the most important part of its business. | Foto: Stine Bidstrup

Did you read?Subscription

Christophe Bourdon had just started as CEO of Leo Pharma when the ground gave way beneath his feet. | Foto: Anders HolstWith effective weight-loss drugs already on the market, patients assigned to placebo groups in clinical trials have less incentive to continue. | Foto: Hollie Adams

Did you read?Subscription

The first generic versions of Ozempic are expected to become available in India as early as this weekend. | Photo: Tom Little

Did you read?Subscription

Add A Comment

Comments are closed.